Last Updated on December 21, 2024 by The Health Master
Form 483
Torrent Pharmaceuticals, a leading Indian pharmaceutical company, has recently faced a minor setback following a routine inspection of its Pithampur-based manufacturing facility followed by Form 483 by the US Food and Drug Administration (USFDA).
The inspection, conducted from September 16-20, aimed to assess the facility’s compliance with Good Manufacturing Practices (GMP) standards.
USFDA Issues Form 483 Observation
At the conclusion of the inspection, the USFDA issued a Form 483 to Torrent Pharmaceuticals.
This document is typically issued when the inspecting agency identifies potential violations of the Food Drug and Cosmetic Act or related regulations.
However, the observation received by Torrent was categorized as procedural in nature, suggesting a minor discrepancy or oversight rather than a major compliance issue.
Company’s Response
Torrent Pharmaceuticals has acknowledged the USFDA’s observation and has committed to addressing it promptly.
The company plans to respond to the regulatory agency within the stipulated timeframe and will work closely with the USFDA to rectify any deficiencies identified during the inspection.
Importance of USFDA Compliance
USFDA compliance is crucial for pharmaceutical companies seeking to market their products in the United States, the world’s largest healthcare market.
Any adverse findings, particularly those related to manufacturing practices, can have significant implications for a company’s reputation and business operations.
In conclusion, while the recent USFDA observation may have caused a temporary concern for Torrent Pharmaceuticals, the company’s commitment to addressing the issue promptly and maintaining high standards of GMP compliance suggests that the impact on its overall operations is likely to be minimal.
As a leading player in the pharmaceutical industry, Torrent will continue to prioritize quality and safety in all aspects of its manufacturing processes.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA Inspection successfully completed at Indian firm Laurus Labs
USFDA inspection finds these lapses at Zydus Lifesciences
USFDA inspection with positive VAI to Dr. Reddy’s Lab for its API facility
Over 340 Pharma Companies overdue for USFDA inspection in India and China
USFDA issues EIR for Marksans Pharma Goa facility
USFDA inspection with positive VAI to Strides Pharma at Chennai
CDSCO approval granted for Durvalumab therapy with specified indication
DCC recommends amendment of Rules to curbing Antimicrobial Resistance
Drug alert: 59 drug samples declared as NSQ in August 2024
PvPI and Adverse Drug Reaction: A Crucial Component of Pharmacy Education: Dr. B Suresh
DCC recommends closely monitoring quality of Eye Drops
Govt revises Guidelines, boosts Support for Pharma Industry
Maharashtra FDA cracks down on ayurvedic manufacturer DMROA
CDSCO Updates Guidance for Zonal, Sub-Zonal, and Port Offices
DCC recommends to address drug Brand Name Confusion in India
USFDA Inspection successfully completed at Indian firm Laurus Labs
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
